AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8767354
Drug: Al-Mg-hydroxide 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-Mg-hydroxide 10 ml
Trial: 1901321
Drug: Fleroxacin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (600 mg/d for 72 hours)
Trial: 7125177
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine base (2.63 mg morphine hydrochloride) in 10 ml 0.9% sodium chloride
Trial: 7125177
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine base in 10 ml 5% glucose
Trial: 7125177
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml 5% glucose as placebo
Trial: 19524752
Drug: Real interferential
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real interferential therapy (IFT), 12 sessions for 4 weeks
Trial: 19524752
Drug: Placebo interferential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo interferential therapy (IFT), 12 sessions for 4 weeks
Trial: 14616423
Drug: Sublingual cobalamin
RxNorm normalized name: mecobalamin Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual cobalamin (500 micro g daily)
Trial: 14616423
Drug: Oral cobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cobalamin (500 micro g daily)
Trial: 14616423
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B complex (two tablets daily)
Trial: 9038554
Drug: Continuous postoperative
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous postoperative femoral nerve block with 0.5% bupivacaine (5 ml/h for 48 h) plus PCA with morphine
Trial: 1824621
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with phenprocumarol
Trial: 1824621
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with acetylsalicylic acid (ASA) plus dipyridamole
Trial: 24237035
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ATRA given 1 hour before and for 7 days following oral typhoid vaccine
Trial: 10517767
Drug: Immunocal (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunocal (20 g/day)
Trial: 8915874
Drug: Bivalent attenuated
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent attenuated cold‐recombinant (CR) vaccine
Trial: 8915874
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent subvirion vaccine (TIV)
Trial: 2065463
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg clopamide
Trial: 6344309
Drug: Pindolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (2.5 mg)
Trial: 6344309
Drug: Terbutaline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.5 mg subcutaneous) after propranolol and pindolol
Trial: 17290057
Drug: Vinblastine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine (5 mg/m2/dose) and Methotrexate (30 mg/m2/dose), administered weekly for 26 weeks and every other week for an additional 26 weeks.
Trial: 22449204
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin and heparin
Trial: 9628448
Drug: Novel antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel antithrombotic treatments (direct thrombin inhibitors, platelet fibrinogen receptor antagonists, low-molecular-weight heparins)
Trial: 30111291
Drug: Transdiagnostic occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic occupational rehabilitation intervention based on Acceptance and Commitment Therapy (3½ weeks duration)
Trial: 27030504
Drug: Autologous dental
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dental pulp stem cell therapy (up to 10 million cells)
Trial: 27030504
Drug: Autologous dental
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dental pulp stem cell therapy (maximum tolerable dose)
Trial: 27030504
Drug: Autologous dental
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dental pulp stem cell therapy combined with 9 weeks of intensive task-specific rehabilitation
Trial: 25319228
Drug: Silexan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan (1 × 160 mg/day)
Trial: 19200613
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/d for 4 weeks
Trial: 19200613
Drug: Ezetimibe 20
RxNorm normalized name: atorvastatin-ezetimibe 20 mg-10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 20 mg/d for 4 weeks
Trial: 1791224
Drug: Peptide T
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide T (D‐ala1‐peptide T amide) infused at 10(‐7) mol/L
Trial: 31564512
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg once daily for 6 days
Trial: 31564512
Drug: Water without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water without any drug (negative control)
Trial: 27769609
Drug: High cardiorespiratory
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cardiorespiratory fitness (CRF) defined as VO2peak >27.5 mL/kg/min in women and >34.4 mL/kg/min in men
Trial: 20828455
Drug: Natural drying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural drying without a topical regimen
Trial: 20828455
Drug: Cleansing with
RxNorm normalized name: Eucerin Hydrating Cleansing With Hyaluronic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing with 95% alcohol after daily bathing
Trial: 17845862
Drug: Subcutaneous carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous carbon dioxide insufflations
Trial: 10965615
Drug: Ulinastatin (600,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (600,000 units in priming solution, 300,000 units in bypass circuit, 300,000 units daily for 5 days post-surgery)
Trial: 9047091
Drug: Metformin (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1.7 g daily for 4 days)
Trial: 8418166
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms of an RSV subunit vaccine composed primarily of F glycoprotein
Trial: 3097693
Drug: L-tryptophan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (3 g)
Trial: 30279397
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil supplement (EPAX: 1600 mg DHA + 400 mg EPA)
Trial: 28977255
Drug: Maximum stepwise
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum stepwise alveolar recruitment associated with PEEP titration (ART strategy)
Trial: 22929542
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (ARDSNet strategy)
Trial: 23441920
Drug: Non-surgical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical therapy plus azithromycin (AZ-Sca)
Trial: 23441920
Drug: Non-surgical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical therapy plus placebo (PB-Sca)
Trial: 19055289
Drug: Compound anesthesia
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound anesthesia of transcutaneous electrical point stimulation and Remifentanil
Trial: 11073741
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg/day; maximum, 500 mg/day)
Trial: 11073741
Drug: Ceftriaxone (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (75 mg/kg/day; maximum, 2.5 g/day)
Trial: 31909417
Drug: Antibiotic indication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic indication documentation during order entry
Trial: 31909417
Drug: Antibiotic indication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic indication documentation for prophylaxis
Trial: 31909417
Drug: Antibiotic indication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic indication documentation for empiric antibiotics
Trial: 31909417
Drug: Antibiotic indication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic indication documentation for definitive antibiotics
Trial: 30835308
Drug: Integrated collaborative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated collaborative care intervention (n=204) including behavioral weight loss treatment, problem-solving therapy, and as-needed antidepressant medications
Trial: 28116579
Drug: Brief intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intervention involving four group sessions of motivational interviewing and cognitive behavioural therapy, initiated 4 weeks prior to release.
Trial: 25323237
Drug: Nitrogen dioxide
RxNorm normalized name: carbon dioxide / nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen dioxide exposure (10 μg · m(‐3))
Trial: 25323237
Drug: PM10 exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM10 exposure (10 μg · m(‐3))
Trial: 25323237
Drug: PM2.5 exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM2.5 exposure (5 μg · m(‐3))
Trial: 24428857
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (15 mg/kg body weight, 100 mg/mL)
Trial: 17418728
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (200/0.5) solution to bring down the hematocrit to 45%
Trial: 12060503
Drug: Doublebase (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublebase (novel hydro-gel emollient)
Trial: 2515215
Drug: Active patch
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active patch (N = 11)
Trial: 2515215
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (N = 9)
Trial: 326447
Drug: Control (dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (dummy preparation)
Trial: 27521672
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DXI; Ozurdex) in combination with ranibizumab (Lucentis)
Trial: 24932567
Drug: Behavioral skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral skills maintenance treatment (BSM)
Trial: 22011511
Drug: Carisbamate 200
RxNorm normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisbamate 200 mg twice-daily
Trial: 22011511
Drug: Carisbamate 600
RxNorm normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisbamate 600 mg twice-daily
Trial: 17180159
Drug: Tomato-based food
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 6 months by HCV patients
Trial: 17180159
Drug: Tomato-based food
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 1 week by healthy subjects
Trial: 15530294
Drug: Salicylic-acid cream
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic-acid cream alone
Trial: 11797074
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nicotine
Trial: 9549664
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation (CF) venlafaxine 50 mg
Trial: 9549664
Drug: Extended-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release formulation (XR) venlafaxine 75 mg
Trial: 9549664
Drug: Intravenous venlafaxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous venlafaxine 10 mg
Trial: 2659953
Drug: Calcitriol 2
RxNorm normalized name: CALCITRIOL 2MCG/ML INJ,1ML AMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 2 mcg/d for 7 days, followed by 100 U/d Salmon Calcitonin + 1 g/d Calcitonin for 21 days, followed by Calcium alone for 2 months
Trial: 25569408
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine (0.5 mg/kg)
Trial: 22938659
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid management (25-35 ml×kg(‐1)×d(‐1))
Trial: 22938659
Drug: Traditional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional fluid management (40-50 ml×kg(‐1)×d(‐1))
Trial: 17989993
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ethanol and 2-propanol disinfectants
Trial: 9892878
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 4 days
Trial: 9892878
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 7 days
Trial: 9892878
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 10 days
Trial: 7740846
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms L-thyroxine injected intraamniotically
Trial: 1723379
Drug: Salmeterol 100
RxNorm normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 100 micrograms inhaled twice daily
Trial: 1723379
Drug: Regular beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular beta 2‐agonist therapy
Trial: 6126423
Drug: Cimetidine 1000
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1000 mg/day
Trial: 6126423
Drug: Oxmetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxmetidine 800 mg/day
Trial: 30893150
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy for high-grade liposarcoma and leiomyosarcoma of the retroperitoneum in the upcoming STRASS-2 study
Trial: 16911869
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 microg dry powder inhalation twice daily for 8 weeks
Trial: 15038626
Drug: Antihypertensive agent
RxNorm normalized name: Antihypertensive agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive agent therapy (AHA)
Trial: 9625400
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg, once daily at bedtime)
Trial: 8174730
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg twice daily for 3 months
Trial: 30376086
Drug: mOPV2 (challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mOPV2 (challenge dose)
Trial: 26333543
Drug: EBFR of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBFR of 200 mL/min
Trial: 26333543
Drug: EBFR of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBFR of 300 mL/min
Trial: 26333543
Drug: EBFR of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBFR of 200, 300 and 400 mL/min
Trial: 18783971
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg kg(‐1) at induction, 1 mg kg(‐1) h(‐1) during surgery, then 1 mg kg(‐1) during 24 h; n=42)
Trial: 15272090
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy and sertraline
Trial: 9827437
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of baclofen
Trial: 7967424
Drug: High quality
RxNorm normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High quality radiation therapy (CESS 86)
Trial: 3191933
Drug: Defibrotide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (single infusion)
Trial: 25850975
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg daily
Trial: 18647845
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine gel
Trial: 31465791
Drug: Placebo (intraurethral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intraurethral aqueous gel)
Trial: 23731775
Drug: Candesartan 8mg
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8mg once daily for 3-6 weeks before ECV and 16mg once daily for 6 months after ECV
Trial: 8874455
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (CMT) with radiotherapy, 5-fluorouracil (1000 mg/m2 for 4 days or 750 mg/m2 for 5 days), and mitomycin (12 mg/m2 on day 1 of the first course)
Trial: 3136331
Drug: sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorbinil (250 mg per day)
Trial: 26159014
Drug: Qi benefiting
RxNorm normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi benefiting blood activating method (QB-BAM) with Shengmai Injection and Tanshinone IIA Injection
Trial: 26159014
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for AECOPD
Trial: 25153084
Drug: Once-daily protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC)
Trial: 25153084
Drug: Once-daily non-nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily non-nucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase inhibitor (NNRTI/NRTI) regimen (EFV+FTC/TDF)
Trial: 25153084
Drug: Twice-daily NNRTI/NRTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily NNRTI/NRTI regimen (EFV+3TC/ZDV)
Trial: 25153084
Drug: Pill-count non-adherence
RxNorm normalized name: Tavist Non-Sedating Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill-count non-adherence
Trial: 15180172
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment with Otovowen (fixed combination of plant‐based tinctures and homeopathic potencies)
Trial: 15180172
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (free combinations of decongestant nose drops, mucolytics, analgesics and antibiotics)
Trial: 15180172
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment with Otovowen
Trial: 9570261
Drug: Omeprazole treatment
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole treatment strategy (10 mg stepping up to 20 mg and 40 mg as required)
Trial: 9570261
Drug: Antacid-alginate/ranitidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid-alginate/ranitidine treatment strategy (10 mL q.d.s. stepping up to ranitidine 150 mg b.d. and 150 mg q.d.s. as required)
Trial: 28659128
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus minimally invasive esophagectomy (MIE)
Trial: 28659128
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus MIE